Paul Liu, Ph.D.
Translational and Functional Genomics Branch
Building 49, Room 3A26
49 Convent Drive
Bethesda, MD 20892
Dr. Liu's laboratory investigates the molecular mechanisms of leukemia, with the long-term goal of translating research findings to improved clinical practices, including better diagnosis and treatment of leukemia and related hematological diseases. A group of diseases that strikes approximately 43,000 Americans each year, leukemias are frequently associated with chromosome abnormalities such as translocations, inversions and deletions. Two genes, CBFB and RUNX1, which encode proteins (CBFb and RUNX1, respectively) that form a dimer for DNA binding and gene expression regulation, are frequent targets of such chromosome abnormalities. Most of Dr. Liu's work focuses on these two genes and the core binding factor (CBF) leukemia, a subset of leukemia caused by chromosome abnormalities in these two genes.
One form of CBF leukemia is associated with an inversion of chromosome 16. Dr. Liu found that this inversion generates a fusion gene between CBFB and MYH11, the gene encoding smooth muscle myosin heavy chain (SMMHC) (Liu et al., Science 1993). To study the fusion gene CBFB-MYH11, Dr. Liu's group generated a knock-in mouse model, which demonstrated that CBFB-MYH11 blocks normal hematopoiesis through dominant repression of Cbfb and Runx1 (Castilla et al., Cell 1996). Using the Cbfb-MYH11 knock-in mice (in which human MYH11 was inserted into mouse Cbfb to recreate the leukemia fusion gene), they demonstrated that CBFB-MYH11 is necessary but not sufficient for leukemogenesis (Castilla et al., Nature Genetics 1999). Dr. Liu's group identified cooperating genetic changes for leukemogenesis with a retroviral insertional mutagenesis approach (Castilla et al., PNAS 2004), and demonstrated that the fusion protein CBFβ-SMMHC blocks lymphoid differentiation, which may explain how the fusion protein only causes myeloid leukemia (Zhao et al., Blood 2007).
More recently, Dr. Liu's group made the novel observation that Cbfb-MYH11 induces acute myeloid leukemia (AML) without dominant repression of Runx1, which was previously believed to be the only function of this fusion gene (Kamikubo et al., Cancer Cell 2010). They also identified novel Cbfb-MYH11 target genes during leukemia development by microarray analysis with cells from Cbfb-MYH11 knock-in mice, and identified leukemia-initiating cells using these new targets (Hyde et al., Blood 2010). With a clinically relevant transgenic mouse model, they demonstrated leukemogenic cooperation between Cbfb-MYH11 and mutationally activated KIT, which are frequently found in human AML cases with chromosome 16 inversion (Zhao et al., Blood 2012). Current and future efforts in Dr. Liu's lab include more functional studies of CBFβ-SMMHC with novel transgenic mouse models.
Mouse, zebrafish, iPS cells, small chemical screensThe zebrafish is a useful model for studying embryonic development, and is easily amenable to large-scale genetic studies. Dr. Liu's group, with the help of the NHGRI Zebrafish Core, headed by Dr. Raman Sood, has used zebrafish to study the roles of several transcription factor genes in hematopoiesis, such as runx1, cbfb, and gata1 (Blake et al., Blood 2000; Lyons et al., PNAS 2002, and Sood et al., Blood 2010). Using a positional cloning/candidate gene approach, they identified a non-sense mutation in gata1 as the cause for a zebrafish mutant with a "bloodless" phenotype (Lyons et al., PNAS 2002). As the first gata1 mutation identified in the zebrafish, this finding demonstrated significant functional conservation between mammalian and zebrafish hematopoiesis. Using a high-throughput reverse genetic screening system they generated a fish line carrying a truncation mutation in runx1, which led to discoveries of novel functions of the gene during hematopoiesis (Sood et al., Blood 2010). Dr. Liu's group also generated fish lines with novel mutations in gata1, which uncovered differential roles of gata1 between primitive and definitive stages of hematopoiesis (Belele et al., Blood 2009). More recently Dr. Liu's lab has generated fish lines with null mutations in cbfb and made novel findings regarding its role in hematopoietic stem cell production (Bresciani, Blood in press). Overall the zebrafish has proven to be an excellent model for dissecting the genetic control of early hematopoiesis, especially the formation of hematopoietic stem cells, from fresh angles and in great detail.
A major current and future project in Dr. Liu's lab is to develop targeted treatments for leukemia. Current treatments for CBF leukemia are associated with significant morbidity and mortality, with a 5-year survival rate of 50-60 percent. It was hypothesized that the interaction between RUNX1 and CBFβ is critical for CBF leukemia and can be targeted for drug development. In collaboration with the NIH Chemical Genomics Center (NCGC), part of the National Center for Advancing Translational Sciences (NCATS), Dr. Liu's group developed high-throughput methods to quantify the RUNX1-CBFβ interaction and screened 243,398 compounds. A lead compound (Ro5-3335) was confirmed as an inhibitor of RUNX1-CBFβ interaction in zebrafish embryos and transcriptional reporter assays. It preferentially killed human CBF leukemia cell lines, and reduced leukemia burden in the mouse CBF leukemia models (Cunningham et al., PNAS 2012). The group is currently conducting structure-activity relationship (SAR) studies to identify more potent analogs and performing additional preclinical tests for eventual clinical trials with human CBF leukemia patients, with support from the Therapeutics for Rare and Neglected Diseases (TRND) Program in NCATS.
The Liu lab is taking a new direction toward application of induced pluripotent stem cell (iPSC) technology to model disease and development of new treatments, especially for diseases without suitable animal models. Supported by the NIH Center for Regenerative Medicine (NCRM) and in collaboration with NIH Intramural Sequencing Center (NISC), the group performed whole genome sequencing of several iPSC lines to demonstrate that the reprogramming process does not generate significant changes at the genomic level (Cheng et al., Cell Stem Cell, 2012). The Liu lab is using the technology to model familial platelet disorder with propensity to acute myeloid leukemia (FPD/AML), caused by mutations in RUNX1, for which good animal models are not available. Dr. Liu hopes to develop cell-based therapies for FPD/AML patients, which may serve as a model for other hematological diseases.
Dr. Liu received his medical degree and residency training in internal medicine in Beijing, China. He then earned his Ph.D. in human genetics from the University of Texas M.D. Anderson Cancer Center in Houston. He received his postdoctoral research training at the University of Michigan before moving in 1993 to NIH's National Center for Human Genome Research, renamed the National Human Genome Research Institute (NHGRI) in 1995.
He has remained at NHGRI - appointed initially as a senior staff fellow, then as a tenure track investigator and since 2001 as a tenured senior investigator. Dr. Liu has been the head of the Oncogenesis and Development Section in NHGRI since 1995. In May 2011, Dr. Liu was appointed as the deputy scientific director of NHGRI. The main focus of Dr. Liu's research over the years has been the mechanism of leukemia development at the molecular level, using genetic and genomic approaches.
Dr. Liu discovered that a CBFB-MYH11 fusion gene is the product of chromosome 16 inversion, a common chromosome abnormality in human acute myeloid leukemia. Using animal models, Dr. Liu has illustrated the importance of CBFB-MYH11 for leukemia development, and how this fusion gene works. His group has also made important discoveries regarding the normal functions of several important leukemia genes.
More recently, Dr. Liu's lab has focused on developing targeted treatments for leukemia. Dr. Liu has received several honors for his achievements, including NIH Director's Award and elections to the American Society for Clinical Investigation and the Association of American Physicians.
Cheng L, Hansen NF, Zhao L, Du Y, Zou C, Donovan FX, Chou BK, Zhou G, Li S, Dowey SN, Ye Z, NISC Comparative Sequencing Program., Chandrasekharappa SC, Yang H, Mullikin JC, Liu PP. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell. 2012;10(3):337-44.
Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, Yedavalli VR, Dehdashti SJ, Reinhold WC, Alemu L, Zhao L, Yeh JR, Sood R, Pommier Y, Austin CP, Jeang KT, Zheng W, Liu P. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction. Proc Natl Acad Sci U S A. 2012;109(36):14592-7.
Bresciani E, Carrington B, Wincovitch S, Jones M, Gore AV, Weinstein BM, Sood R, Liu PP. CBFβ and RUNX1 are required at 2 different steps during the development of hematopoietic stem cells in zebrafish. Blood. 2014;124(1):70-8.
Connelly JP, Kwon EM, Gao Y, Trivedi NS, Elkahloun AG, Horwitz MS, Cheng L, Liu PP. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects. Blood. 2014;124(12):1926-30.
Kwon EM, Connelly JP, Hansen NF, Donovan FX, Winkler T, Davis BW, Alkadi H, Chandrasekharappa SC, Dunbar CE, Mullikin JC, Liu P. iPSCs and fibroblast subclones from the same fibroblast population contain comparable levels of sequence variations. Proc Natl Acad Sci U S A. 2017;114(8):1964-1969.
Related Scientific Focus Areas
Genetics and Genomics
This page was last updated on August 25th, 2017